Precision BioSciences, Inc. (DTIL): רווח נקי למניה (EPS TTM)

The rolling 12-month EPS chart correlates with the strategic engagement of Precision BioSciences (DTIL) with pharmaceutical behemoths. Negative cash flow and the current trial stage confirm the absence of current earnings, while the -1.29 level reflects the current magnitude of this metric. Meanwhile, unique patents for synthetic nucleases create high business value through the long-term licensing of genome editing technologies.

Investors assess business resilience through the ability to generate real cash flow per common share. This indicator aggregates net income over the last four quarters, excluding the impact of one-time factors. For Precision BioSciences (DTIL), such costs are associated with the implementation of ARCUS AI platforms and the robotization of genome bioscreening. Analyzing the rolling annual earnings per share allows for tracking the efficiency of these technological investments. The price action on this chart determines the company's survival threshold.